Tamsulosin in urology: beyond benign prostatic hyperplasia

G. G. Laxman Prabhu, Hiren Prajapati, Alok Chaturvedi, Nilanj Dave, Amit B. Jain

Research output: Contribution to journalReview article

Abstract

Tamsulosin, a third-generation uroselective α 1A adrenergic receptor blocker (antagonist), has been approved for the treatment of signs and symptoms of benign prostatic hyperplasia for more than two decades. Apart from this approved use, more recent evidence has been published regarding the off-label use of tamsulosin in various other urological conditions. However, further research is needed regarding the use of tamsulosin in these indications. This review highlights the possible therapeutic uses of tamsulosin for the management of various urological conditions.

Original languageEnglish
Pages (from-to)181-184
Number of pages4
JournalDrugs and Therapy Perspectives
Volume35
Issue number4
DOIs
Publication statusPublished - 10-04-2019

Fingerprint

tamsulosin
Prostatic Hyperplasia
Urology
Adrenergic Antagonists
Off-Label Use
Therapeutic Uses
Signs and Symptoms
Research

All Science Journal Classification (ASJC) codes

  • Pharmacology (medical)

Cite this

Laxman Prabhu, G. G., Prajapati, H., Chaturvedi, A., Dave, N., & Jain, A. B. (2019). Tamsulosin in urology: beyond benign prostatic hyperplasia. Drugs and Therapy Perspectives, 35(4), 181-184. https://doi.org/10.1007/s40267-019-00611-1
Laxman Prabhu, G. G. ; Prajapati, Hiren ; Chaturvedi, Alok ; Dave, Nilanj ; Jain, Amit B. / Tamsulosin in urology : beyond benign prostatic hyperplasia. In: Drugs and Therapy Perspectives. 2019 ; Vol. 35, No. 4. pp. 181-184.
@article{90b2b64fabc3444f90602969ceb0ab54,
title = "Tamsulosin in urology: beyond benign prostatic hyperplasia",
abstract = "Tamsulosin, a third-generation uroselective α 1A adrenergic receptor blocker (antagonist), has been approved for the treatment of signs and symptoms of benign prostatic hyperplasia for more than two decades. Apart from this approved use, more recent evidence has been published regarding the off-label use of tamsulosin in various other urological conditions. However, further research is needed regarding the use of tamsulosin in these indications. This review highlights the possible therapeutic uses of tamsulosin for the management of various urological conditions.",
author = "{Laxman Prabhu}, {G. G.} and Hiren Prajapati and Alok Chaturvedi and Nilanj Dave and Jain, {Amit B.}",
year = "2019",
month = "4",
day = "10",
doi = "10.1007/s40267-019-00611-1",
language = "English",
volume = "35",
pages = "181--184",
journal = "Drugs and Therapy Perspectives",
issn = "1172-0360",
publisher = "Adis International Ltd",
number = "4",

}

Laxman Prabhu, GG, Prajapati, H, Chaturvedi, A, Dave, N & Jain, AB 2019, 'Tamsulosin in urology: beyond benign prostatic hyperplasia', Drugs and Therapy Perspectives, vol. 35, no. 4, pp. 181-184. https://doi.org/10.1007/s40267-019-00611-1

Tamsulosin in urology : beyond benign prostatic hyperplasia. / Laxman Prabhu, G. G.; Prajapati, Hiren; Chaturvedi, Alok; Dave, Nilanj; Jain, Amit B.

In: Drugs and Therapy Perspectives, Vol. 35, No. 4, 10.04.2019, p. 181-184.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Tamsulosin in urology

T2 - beyond benign prostatic hyperplasia

AU - Laxman Prabhu, G. G.

AU - Prajapati, Hiren

AU - Chaturvedi, Alok

AU - Dave, Nilanj

AU - Jain, Amit B.

PY - 2019/4/10

Y1 - 2019/4/10

N2 - Tamsulosin, a third-generation uroselective α 1A adrenergic receptor blocker (antagonist), has been approved for the treatment of signs and symptoms of benign prostatic hyperplasia for more than two decades. Apart from this approved use, more recent evidence has been published regarding the off-label use of tamsulosin in various other urological conditions. However, further research is needed regarding the use of tamsulosin in these indications. This review highlights the possible therapeutic uses of tamsulosin for the management of various urological conditions.

AB - Tamsulosin, a third-generation uroselective α 1A adrenergic receptor blocker (antagonist), has been approved for the treatment of signs and symptoms of benign prostatic hyperplasia for more than two decades. Apart from this approved use, more recent evidence has been published regarding the off-label use of tamsulosin in various other urological conditions. However, further research is needed regarding the use of tamsulosin in these indications. This review highlights the possible therapeutic uses of tamsulosin for the management of various urological conditions.

UR - http://www.scopus.com/inward/record.url?scp=85062948883&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062948883&partnerID=8YFLogxK

U2 - 10.1007/s40267-019-00611-1

DO - 10.1007/s40267-019-00611-1

M3 - Review article

AN - SCOPUS:85062948883

VL - 35

SP - 181

EP - 184

JO - Drugs and Therapy Perspectives

JF - Drugs and Therapy Perspectives

SN - 1172-0360

IS - 4

ER -

Laxman Prabhu GG, Prajapati H, Chaturvedi A, Dave N, Jain AB. Tamsulosin in urology: beyond benign prostatic hyperplasia. Drugs and Therapy Perspectives. 2019 Apr 10;35(4):181-184. https://doi.org/10.1007/s40267-019-00611-1